Ji Yun, Hocker James D, Gattinoni Luca
Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, USA.
Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, USA.
Semin Immunol. 2016 Feb;28(1):45-53. doi: 10.1016/j.smim.2015.11.006. Epub 2015 Dec 20.
Adoptive T cell-based immunotherapies can mediate complete and durable regressions in patients with advanced cancer, but current response rates remain inadequate. Maneuvers to improve the fitness and antitumor efficacy of transferred T cells have been under extensive exploration in the field. Small non-coding microRNAs have emerged as critical modulators of immune system homeostasis and T cell immunity. Here, we summarize recent advances in our understanding of the role of microRNAs in regulating T cell activation, differentiation, and function. We also discuss how microRNA therapeutics could be employed to fine-tune T cell receptor signaling and enhance T cell persistence and effector functions, paving the way for the next generation of adoptive immunotherapies.
基于过继性T细胞的免疫疗法可介导晚期癌症患者实现完全且持久的肿瘤消退，但目前的缓解率仍不尽人意。该领域一直在广泛探索提高转移T细胞适应性和抗肿瘤功效的策略。小型非编码微小RNA已成为免疫系统稳态和T细胞免疫的关键调节因子。在此，我们总结了近期在理解微小RNA在调节T细胞活化、分化和功能方面作用的研究进展。我们还讨论了如何利用微小RNA疗法来微调T细胞受体信号传导，增强T细胞持久性和效应功能，为下一代过继性免疫疗法铺平道路。
